Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotagliflozin - Lexicon Pharmaceuticals

Drug Profile

Sotagliflozin - Lexicon Pharmaceuticals

Alternative Names: [14C]-LX4211; LP-802034; LX-4211; SAR 439954; Zynquista

Latest Information Update: 05 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Lexicon Pharmaceuticals; Sanofi
  • Class Alcohols; Antihyperglycaemics; Chlorobenzenes; Glycosides; Heart failure therapies; Phenyl ethers; Pyrans; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Type 1 diabetes mellitus
  • Phase III Heart failure; Type 2 diabetes mellitus

Most Recent Events

  • 02 Dec 2019 The Office of New Drugs of the US FDA denies Lexicon Pharmaceuticals Formal Dispute Resolution Request relating to the NDA for Type 1 diabetes mellitus (Adjunctive treatment)
  • 08 Nov 2019 Lexicon terminates its license with Sanofi for the worldwide development and commercialisation of sotagliflozin
  • 14 Oct 2019 Sanofi completes the phase III SOTA-CKD3 trial in Type-2 diabetes mellitus with moderate renal impairment in USA, Canada, Ukraine, Spain, South Africa, Russia, Romania, Poland, Mexico, Italy, Israel, Germany, Colombia, Brazil, Argentina and Hungary (PO, Tablet) (NCT03242252)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top